Gastro-Enteric-Pancreatic Neuroendocrine Tumor Treatment: Actinium-225-DOTATATE and Combined Therapies.

Swayamjeet Satapathy, Kunal Ramesh Chandekar, Chandrasekhar Bal

Journal: PET clinics 2023;18(2):215-221

PMID: 36858746

Full Text on Elsevier Science View on PubMed

Abstract

The role of lutetium-177-DOTATATE in advanced well-differentiated gastro-entero-pancreatic neuroendocrine tumors is well established. However, there is a scope for improving treatment outcomes. Actinium-225-DOTATATE is a form of targeted alpha therapy (TAT) that results in more efficient tumor cell killing owing to the substantially higher linear energy transfer of alpha particles. Systemic TAT is also safe given that the shorter path length of the alpha particles spares the surrounding healthy tissue and results in relatively fewer adverse events. Combination therapies with radiosensitizing and other chemotherapeutic agents have also gained popularity, especially in the setting of higher grade and fluorodeoxyglucose-avid tumors.

Address: Department of Nuclear Medicine, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110029, India.; Department of Nuclear Medicine, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110029, India. Electronic address: [email protected].

DOI: 10.1016/j.cpet.2022.11.004

Link outs

Free resources

Medical:

https://medlineplus.gov/pancreaticcancer.html

Subscription / membership required

Full Text Sources:

MeSH Terms: Humans, Neuroendocrine Tumors, Pancreatic Neoplasms, Actinium